Belloni Silvia, Arrigoni Cristina, Arcidiacono Marco Alfredo, Boschi Giovanni, Leonetti Alessandro, Allevato Maria, Diamanti Orejeta, Cardone Chiara, Girardi Daniele, Ferrante Sergio, Strada Daniela, Bonalumi Silvia, Pisano Elena, Maisola Paola, Villa Giulia, Magon Arianna, Conte Gianluca, Ducoli Stefania, Fadda Marco, Michele Tedeschi, Caruso Rosario
Department of Public Health, Experimental and Forensic Medicine, Section of Hygiene, University of Pavia, Pavia, Italy.
Medical Unit, University Hospital of Parma, Parma, Italy.
Int J Nurs Sci. 2025 Feb 16;12(3):276-284. doi: 10.1016/j.ijnss.2025.02.011. eCollection 2025 May.
This study aimed to analyze the prevalence of long-term central line-associated bloodstream infections (CLABSI) among hospitalized adults with cancer in Italy and compare the characteristics of patients who required long-term central venous access device (LCVAD) substitution due to prior CLABSI with those who had never experienced CLABSI.
The study was conducted in hospitals across northern and central Italy using a multicenter, observational, cross-sectional design from March to September 2021. A total of 174 adults with cancer were included. Data were collected through electronic case report forms, including demographic, clinical, treatment-related, and catheter-related variables. Propensity score matching (PSM) was used to compare the characteristics of patients who underwent LCVAD substitution due to previous CLABSI with those who never experienced CLABSI. Multiple correspondence analysis (MCA) was conducted to explore the patterns within matched subgroups.
The prevalence of CLABSI was 3 %, and 5.2 % of patients required LCVAD substitution due to prior CLABSI. After applying PSM, the groups were successfully balanced for sex, age, presence of metastases, comorbidities, BMI, received treatments, corticosteroid therapy, ongoing antibiotics, hormone therapy, type of LCVAD, lumens, and utilization frequency. Hematologic cancer was more frequent in the CLABSI group (44.4 %) compared to the non-infective group (0), with a statistically significant difference ( = 0.045). MCA revealed potential patterns among matched subgroups but did not identify statistically significant associations: patients with previous LCVAD substitution were more frequently associated with a history of prior infections, ongoing antibiotic therapy, and unspecified primary lesion locations; conversely, patients who never experienced CLABSI tended to cluster around characteristics such as hormone therapy and corticosteroid therapy.
These findings emphasize the importance of continuous monitoring, individualized infection prevention strategies in oncology nursing practice. Future research with larger datasets is needed to validate these findings and develop tailored interventions to reduce CLABSI risks.
本研究旨在分析意大利住院成年癌症患者中长期中心静脉导管相关血流感染(CLABSI)的患病率,并比较因先前CLABSI而需要更换长期中心静脉通路装置(LCVAD)的患者与从未发生过CLABSI的患者的特征。
本研究于2021年3月至9月在意大利北部和中部的医院进行,采用多中心、观察性、横断面设计。共纳入174名成年癌症患者。通过电子病例报告表收集数据,包括人口统计学、临床、治疗相关和导管相关变量。倾向评分匹配(PSM)用于比较因先前CLABSI而接受LCVAD更换的患者与从未发生过CLABSI的患者的特征。进行多重对应分析(MCA)以探索匹配亚组中的模式。
CLABSI的患病率为3%,5.2%的患者因先前的CLABSI而需要更换LCVAD。应用PSM后,两组在性别、年龄、转移灶的存在、合并症、BMI、接受的治疗、皮质类固醇治疗、正在使用的抗生素、激素治疗、LCVAD类型、管腔和使用频率方面成功达到平衡。与非感染组(0)相比,CLABSI组血液系统癌症更为常见(44.4%),差异有统计学意义(P = 0.045)。MCA揭示了匹配亚组中的潜在模式,但未发现统计学上的显著关联:先前接受LCVAD更换的患者更常与先前感染史、正在进行的抗生素治疗和未明确的原发病变部位相关;相反,从未发生过CLABSI的患者倾向于聚集在激素治疗和皮质类固醇治疗等特征周围。
这些发现强调了在肿瘤护理实践中持续监测、个性化感染预防策略的重要性。需要更大数据集的未来研究来验证这些发现并制定针对性干预措施以降低CLABSI风险。